The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the ...

This approval is Biocon's seventh U.S. biosimilar, enhancing their oncology portfolio and commitment to affordable biologics. The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, announced a strategic cooperation agreement with Polpharma Biologics to advance the end-to-end development and ...

The US Food and Drug Administration ... to learn a new method of administration can be a game changer in increasing patient access to adalimumab.” The designation comes less than two weeks after the ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year across its global operations.

Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar ... but that was approved as under a new drug application, not as a biosimilar, and so also needs ...

BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant ...

Fresenius’ operating company Fresenius Kabi reached a global settlement with Amgen concerning their denosumab biosimilars ... The FDA approval is based on comprehensive analytical development ...